These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24320998)

  • 1. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582).
    Hennessy EJ; Adam A; Aquila BM; Castriotta LM; Cook D; Hattersley M; Hird AW; Huntington C; Kamhi VM; Laing NM; Li D; MacIntyre T; Omer CA; Oza V; Patterson T; Repik G; Rooney MT; Saeh JC; Sha L; Vasbinder MM; Wang H; Whitston D
    J Med Chem; 2013 Dec; 56(24):9897-919. PubMed ID: 24320998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.
    Zobel K; Wang L; Varfolomeev E; Franklin MC; Elliott LO; Wallweber HJ; Okawa DC; Flygare JA; Vucic D; Fairbrother WJ; Deshayes K
    ACS Chem Biol; 2006 Sep; 1(8):525-33. PubMed ID: 17168540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents.
    Peng Y; Sun H; Lu J; Liu L; Cai Q; Shen R; Yang CY; Yi H; Wang S
    J Med Chem; 2012 Jan; 55(1):106-14. PubMed ID: 22148838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization.
    Lecis D; Mastrangelo E; Belvisi L; Bolognesi M; Civera M; Cossu F; De Cesare M; Delia D; Drago C; Manenti G; Manzoni L; Milani M; Moroni E; Perego P; Potenza D; Rizzo V; Scavullo C; Scolastico C; Servida F; Vasile F; Seneci P
    Bioorg Med Chem; 2012 Nov; 20(22):6709-23. PubMed ID: 23062821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design and molecular profiling of Smac-mimetics selective for cellular IAPs.
    Corti A; Milani M; Lecis D; Seneci P; de Rosa M; Mastrangelo E; Cossu F
    FEBS J; 2018 Sep; 285(17):3286-3298. PubMed ID: 30055105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.
    Perez HL; Chaudhry C; Emanuel SL; Fanslau C; Fargnoli J; Gan J; Kim KS; Lei M; Naglich JG; Traeger SC; Vuppugalla R; Wei DD; Vite GD; Talbott RL; Borzilleri RM
    J Med Chem; 2015 Feb; 58(3):1556-62. PubMed ID: 25584393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
    Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
    Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognition of Smac-mimetic compounds by the BIR domain of cIAP1.
    Cossu F; Malvezzi F; Canevari G; Mastrangelo E; Lecis D; Delia D; Seneci P; Scolastico C; Bolognesi M; Milani M
    Protein Sci; 2010 Dec; 19(12):2418-29. PubMed ID: 20954235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smac mimetics as IAP antagonists.
    Fulda S
    Semin Cell Dev Biol; 2015 Mar; 39():132-8. PubMed ID: 25550219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2.
    Cossu F; Mastrangelo E; Milani M; Sorrentino G; Lecis D; Delia D; Manzoni L; Seneci P; Scolastico C; Bolognesi M
    Biochem Biophys Res Commun; 2009 Jan; 378(2):162-7. PubMed ID: 18992220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases.
    Zhang B; Nikolovska-Coleska Z; Zhang Y; Bai L; Qiu S; Yang CY; Sun H; Wang S; Wu Y
    J Med Chem; 2008 Dec; 51(23):7352-5. PubMed ID: 19012392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics.
    Lee EW; Seong D; Seo J; Jeong M; Lee HK; Song J
    Cell Death Differ; 2015 Sep; 22(9):1463-76. PubMed ID: 25613375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homo- and heterodimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part I: Synthesis.
    Manzoni L; Belvisi L; Bianchi A; Conti A; Drago C; de Matteo M; Ferrante L; Mastrangelo E; Perego P; Potenza D; Scolastico C; Servida F; Timpano G; Vasile F; Rizzo V; Seneci P
    Bioorg Med Chem; 2012 Nov; 20(22):6687-708. PubMed ID: 23036335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines.
    Polanski R; Vincent J; Polanska UM; Petreus T; Tang EK
    Cell Death Dis; 2015 Oct; 6(10):e1893. PubMed ID: 26426685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of small-molecule Smac mimetics as IAP antagonists.
    Wang S
    Curr Top Microbiol Immunol; 2011; 348():89-113. PubMed ID: 21072626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer.
    Moon JH; Shin JS; Hong SW; Jung SA; Hwang IY; Kim JH; Choi EK; Ha SH; Kim JS; Kim KM; Hong DW; Kim D; Kim YS; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Hattersley M; Jin DH; Kim TW
    Oncotarget; 2015 Sep; 6(29):26895-908. PubMed ID: 26314849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors.
    Wang J; Li W
    J Pharmacol Exp Ther; 2014 May; 349(2):319-29. PubMed ID: 24623800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).
    Flygare JA; Beresini M; Budha N; Chan H; Chan IT; Cheeti S; Cohen F; Deshayes K; Doerner K; Eckhardt SG; Elliott LO; Feng B; Franklin MC; Reisner SF; Gazzard L; Halladay J; Hymowitz SG; La H; LoRusso P; Maurer B; Murray L; Plise E; Quan C; Stephan JP; Young SG; Tom J; Tsui V; Um J; Varfolomeev E; Vucic D; Wagner AJ; Wallweber HJ; Wang L; Ware J; Wen Z; Wong H; Wong JM; Wong M; Wong S; Yu R; Zobel K; Fairbrother WJ
    J Med Chem; 2012 May; 55(9):4101-13. PubMed ID: 22413863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.
    Sun H; Lu J; Liu L; Yang CY; Wang S
    ACS Chem Biol; 2014 Apr; 9(4):994-1002. PubMed ID: 24521431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of new bivalent quinazoline analogues as IAP antagonists.
    Bae I; Kim D; Choi J; Kim J; Kim M; Park B; Kim YH; Ahn YG; Hyung Kim H; Kim DK
    Bioorg Med Chem Lett; 2021 Feb; 34():127676. PubMed ID: 33166687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.